BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Salhy M, Hatlebakk JG, Gilja OH, Hausken T. Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. Expert Rev Gastroenterol Hepatol. 2014;8:435-443. [PMID: 24580043 DOI: 10.1586/17474124.2014.888952] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Dale HF, Jensen C, Hausken T, Valeur J, Hoff DAL, Lied GA. Effects of a Cod Protein Hydrolysate Supplement on Symptoms, Gut Integrity Markers and Fecal Fermentation in Patients with Irritable Bowel Syndrome. Nutrients 2019;11:E1635. [PMID: 31319590 DOI: 10.3390/nu11071635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 El-Salhy M, Patcharatrakul T, Gonlachanvit S. Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century. World J Gastroenterol 2021; 27(22): 2921-2943 [PMID: 34168399 DOI: 10.3748/wjg.v27.i22.2921] [Reference Citation Analysis]
3 El-Salhy M, Hausken T, Gilja OH, Hatlebakk JG. The possible role of gastrointestinal endocrine cells in the pathophysiology of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2017;11:139-148. [PMID: 27927062 DOI: 10.1080/17474124.2017.1269601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
4 El-Salhy M. Recent advances in the diagnosis of irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2015;9:1161-74. [PMID: 26162959 DOI: 10.1586/17474124.2015.1067138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
5 Mazzawi T, El-Salhy M. Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance. Exp Biol Med (Maywood) 2017;242:1355-62. [PMID: 28737477 DOI: 10.1177/1535370217699537] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Zang KH, Shao YY, Zuo X, Rao Z, Qin HY. Oridonin Alleviates Visceral Hyperalgesia in a Rat Model of Postinflammatory Irritable Bowel Syndrome: Role of Colonic Enterochromaffin Cell and Serotonin Availability. J Med Food. 2016;19:586-592. [PMID: 27111743 DOI: 10.1089/jmf.2015.3595] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
7 Jang SH, Ryu HS, Choi SC, Lee SY. Psychological Factors Influence the Irritable Bowel Syndrome and Their Effect on Quality of Life among Firefighters in South Korea. Psychiatry Investig 2017;14:434-40. [PMID: 28845170 DOI: 10.4306/pi.2017.14.4.434] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 El-Salhy M, Gilja OH, Hatlebakk JG. Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting. Mol Med Rep. 2019;20:787-794. [PMID: 31180516 DOI: 10.3892/mmr.2019.10284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Sebastián Domingo JJ. Síndrome del intestino irritable: lo (pen)último sobre lo que se está investigando. Medicina Clínica 2016;146:260-2. [DOI: 10.1016/j.medcli.2015.10.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 El-Salhy M, Hatlebakk JG, Hausken T. Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Neuropeptides. 2020;79:101973. [PMID: 31727345 DOI: 10.1016/j.npep.2019.101973] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 El-Salhy M, Hatlebakk JG, Gilja OH, Hausken T. Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides. 2015;67:12-19. [PMID: 25765365 DOI: 10.1016/j.peptides.2015.02.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
12 El-Salhy M, Hatlebakk JG, Hausken T. Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities. World J Gastroenterol 2015; 21(32): 9577-9587 [PMID: 26327765 DOI: 10.3748/wjg.v21.i32.9577] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
13 El-Salhy M. Recent developments in the pathophysiology of irritable bowel syndrome. World J Gastroenterol 2015; 21(25): 7621-7636 [PMID: 26167065 DOI: 10.3748/wjg.v21.i25.7621] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
14 El-Salhy M, Gilja OH, Hatlebakk JG, Hausken T. Stomach antral endocrine cells in patients with irritable bowel syndrome. Int J Mol Med. 2014;34:967-974. [PMID: 25110039 DOI: 10.3892/ijmm.2014.1887] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
15 El-Salhy M, Hausken T, Hatlebakk JG. Density of Musashi‑1‑positive stem cells in the stomach of patients with irritable bowel syndrome. Mol Med Rep 2020;22:3135-40. [PMID: 32945509 DOI: 10.3892/mmr.2020.11412] [Reference Citation Analysis]
16 Tang Y, Chen A, Chen Y, Guo L, Dai H, Huang Y, Chen Q, Lin C. Zeta Inhibitory Peptide as a Novel Therapy to Control Chronic Visceral Hypersensitivity in a Rat Model. PLoS One 2016;11:e0163324. [PMID: 27776136 DOI: 10.1371/journal.pone.0163324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
17 Mazzawi T, Gundersen D, Hausken T, El-Salhy M. Increased chromogranin a cell density in the large intestine of patients with irritable bowel syndrome after receiving dietary guidance. Gastroenterol Res Pract. 2015;823897. [PMID: 25918524 DOI: 10.1155/2015/823897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
18 Mazzawi T, Hausken T, Gundersen D, El-Salhy M. Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome. Eur J Clin Nutr. 2015;69:519-524. [PMID: 25097003 DOI: 10.1038/ejcn.2014.151] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
19 Mazzawi T, El-Salhy M. Effect of diet and individual dietary guidance on gastrointestinal endocrine cells in patients with irritable bowel syndrome (Review). Int J Mol Med 2017;40:943-52. [PMID: 28849091 DOI: 10.3892/ijmm.2017.3096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 Ohlsson B. Theories behind the effect of starch‑ and sucrose‑reduced diets on gastrointestinal symptoms in irritable bowel syndrome (Review). Mol Med Rep 2021;24:732. [PMID: 34414452 DOI: 10.3892/mmr.2021.12372] [Reference Citation Analysis]
21 El-Salhy M, Ystad SO, Mazzawi T, Gundersen D. Dietary fiber in irritable bowel syndrome (Review). Int J Mol Med 2017;40:607-13. [PMID: 28731144 DOI: 10.3892/ijmm.2017.3072] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 9.2] [Reference Citation Analysis]
22 Mazzawi T, Hausken T, Gundersen D, El-Salhy M. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome. Eur J Clin Nutr. 2016;70:175-181. [PMID: 26603880 DOI: 10.1038/ejcn.2015.191] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
23 Mazzawi T, Gundersen D, Hausken T, El-Salhy M. Increased gastric chromogranin A cell density following changes to diets of patients with irritable bowel syndrome. Mol Med Rep. 2014;10:2322-2326. [PMID: 25174455 DOI: 10.3892/mmr.2014.2498] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
24 Mazzawi T, El-Salhy M. Changes in small intestinal chromogranin A-immunoreactive cell densities in patients with irritable bowel syndrome after receiving dietary guidance. Int J Mol Med. 2016;37:1247-1253. [PMID: 26987104 DOI: 10.3892/ijmm.2016.2523] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
25 Saidi K, Nilholm C, Roth B, Ohlsson B. A carbohydrate-restricted diet for patients with irritable bowel syndrome lowers serum C-peptide, insulin, and leptin without any correlation with symptom reduction. Nutr Res 2021;86:23-36. [PMID: 33450656 DOI: 10.1016/j.nutres.2020.12.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Saeed F, Salehi M, Alavi K, Ajdarkosh H, Kashaninasab F, Nasr Esfahani F. Defense Mechanisms in Patients with Irritable Bowel Syndrome and Their Relationship with Symptom Severity and Quality of Life. Middle East J Dig Dis 2019;11:158-65. [PMID: 31687115 DOI: 10.15171/mejdd.2019.143] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 El-Salhy M, Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2018;12:439-445. [PMID: 29493330 DOI: 10.1080/17474124.2018.1447380] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
28 El-Salhy M, Gundersen D. Diet in irritable bowel syndrome. Nutr J. 2015;14:36. [PMID: 25880820 DOI: 10.1186/s12937-015-0022-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
29 El-Salhy M, Patcharatrakul T, Hatlebakk JG, Hausken T, Gilja OH, Gonlachanvit S. Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome. Scand J Gastroenterol 2017;52:691-7. [PMID: 28346031 DOI: 10.1080/00365521.2017.1305123] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
30 El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11. [PMID: 31394793 DOI: 10.3390/nu11081824] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]